These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 29215820)

  • 41. A randomized controlled trial of pegylated interferon-alpha with tenofovir disoproxil fumarate for hepatitis B e antigen-negative chronic hepatitis B: A 48-week follow-up study.
    Bahardoust M; Mokhtare M; Barati M; Bagheri-Hosseinabadi Z; Karimi Behnagh A; Keyvani H; Agah S
    J Infect Chemother; 2020 Dec; 26(12):1265-1271. PubMed ID: 32762882
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study.
    Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Kim K; Kitrinos KM; Subramanian GM; McHutchison JG; Yee LJ; Elkhashab M; Berg T; Sporea I; Yurdaydin C; Husa P; Jablkowski MS; Gane E
    J Hepatol; 2017 Jan; 66(1):11-18. PubMed ID: 27545497
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Effect of tenofovir disoproxil fumarate antiviral therapy on virus-specific CD8+T Cells function in patients with chronic hepatitis B].
    Duan SP; Zhu LH; Hou LJ; Wang HW; Zhu XW; Hao J
    Zhonghua Gan Zang Bing Za Zhi; 2021 May; 29(5):421-426. PubMed ID: 34107578
    [No Abstract]   [Full Text] [Related]  

  • 44. HBV quasispecies composition in Lamivudine-failed chronic hepatitis B patients and its influence on virological response to Tenofovir-based rescue therapy.
    Banerjee P; Chakraborty A; Mondal RK; Khatun M; Datta S; Das K; Pandit P; Mukherjee S; Banerjee S; Ghosh S; Chakrabarti S; Chowdhury A; Datta S
    Sci Rep; 2017 Mar; 7():44742. PubMed ID: 28303969
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy.
    Lavocat F; Dény P; Pichoud C; Al Hawajri N; Kitrinos K; Borroto-Esoda K; Zoulim F
    J Hepatol; 2013 Oct; 59(4):684-95. PubMed ID: 23742912
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir.
    Fong TL; Tien A; Jo KJ; Chu D; Cheung E; Mena EA; Phan QQ; Yu AS; Mohammed W; Velasco A; LeDuc VH; Nguyen N; Han SB; Chang M; Bae HS; Cho YW; Tong MJ; Cooper SL
    Dig Dis Sci; 2015 Nov; 60(11):3465-72. PubMed ID: 26138653
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term Efficacy of Tenofovir Disoproxil Fumarate Monotherapy for Multidrug-Resistant Chronic HBV infection.
    Lee HW; Park JY; Lee JW; Yoon KT; Kim CW; Park H; Kim YS; Paik SK; Lee JI; Kim BK; Han KH; Ahn SH
    Clin Gastroenterol Hepatol; 2019 Jun; 17(7):1348-1355.e2. PubMed ID: 30613003
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tenofovir rescue therapy in chronic hepatitis B patients who failed previous nucleoside analogue treatment.
    Kozielewicz D; Halota W; Wietlicka-Piszcz M
    Hepatol Int; 2016 Mar; 10(2):302-9. PubMed ID: 26612013
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result.
    Cai S; Yu T; Jiang Y; Zhang Y; Lv F; Peng J
    Clin Exp Med; 2016 Aug; 16(3):429-36. PubMed ID: 26164128
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Amino acid similarities and divergences in the small surface proteins of genotype C hepatitis B viruses between nucleos(t)ide analogue-naïve and lamivudine-treated patients with chronic hepatitis B.
    Ding H; Liu B; Zhao C; Yang J; Yan C; Yan L; Zhuang H; Li T
    Antiviral Res; 2014 Feb; 102():29-34. PubMed ID: 24316031
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B: 3-year trial.
    Lim YS; Lee YS; Gwak GY; Byun KS; Kim YJ; Choi J; An J; Lee HC; Yoo BC; Kwon SY
    Hepatology; 2017 Sep; 66(3):772-783. PubMed ID: 28370419
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study.
    Zoulim F; Carosi G; Greenbloom S; Mazur W; Nguyen T; Jeffers L; Brunetto M; Yu S; Llamoso C
    J Hepatol; 2015 Jan; 62(1):56-63. PubMed ID: 25176615
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [A study of the effectiveness of nucleos(t)ide analogues in the treatment of HBeAg- positive chronic hepatitis B with normal alanine aminotransferase and high level of HBV DNA].
    Wang FD; Zhou J; Zhang DM; Wang ML; Tao YC; Wu DB; Tang H; Chen EQ
    Zhonghua Gan Zang Bing Za Zhi; 2022 Apr; 30(4):389-394. PubMed ID: 35545563
    [No Abstract]   [Full Text] [Related]  

  • 54. A long-term multicenter study: Entecavir versus Tenofovir in treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients.
    Kayaaslan B; Akinci E; Ari A; Tufan ZK; Alpat SN; Gunal O; Tosun S; Guner R; Tabak F
    Clin Res Hepatol Gastroenterol; 2018 Feb; 42(1):40-47. PubMed ID: 28757048
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs.
    Suzuki F; Suzuki Y; Hosaka T; Sezaki H; Akuta N; Fujiyama S; Kawamura Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Suzuki Y; Kumada H
    J Gastroenterol; 2017 May; 52(5):641-651. PubMed ID: 27699721
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of tenofovir switch therapy for nucleos(t)ide-experienced patients with chronic hepatitis B.
    Lo AO; Wong VW; Wong GL; Tse YK; Chan HY; Chan HL
    Aliment Pharmacol Ther; 2015 Jun; 41(11):1190-9. PubMed ID: 25825194
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prevalence and risk factors for viral blipping in chronic hepatitis B patients treated with nucleos (t) ide analogues.
    Brahmania M; Brouwer WP; Hansen T; Mazzulli T; Feld J; Wong D; Kowgier M; Janssen HL
    J Viral Hepat; 2016 Dec; 23(12):1003-1008. PubMed ID: 27502526
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of the long-term efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naïve HBeAg-positive patients with chronic hepatitis B: A large, multicentre, randomized controlled trials.
    Cai D; Pan C; Yu W; Dang S; Li J; Wu S; Jiang N; Wang M; Zhang Z; Lin F; Xin S; Yang Y; Shen B; Ren H
    Medicine (Baltimore); 2019 Jan; 98(1):e13983. PubMed ID: 30608440
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F
    N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
    Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
    Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.